Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Completed · Phase 2 · Has a placebo group

Conditions studied: Advanced or Inoperable Gastric Cancer

In brief

This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A participants received BGB-290; in Arm B participants received placebo. The purpose of this study is to show that BGB-290 (pamiparib) (versus placebo) will improve progression-free survival (PFS) in participants with advanced or inoperable gastric cancer.

Key facts

Study ID
NCT03427814
Run by
BeiGene
People needed
136
Starts
2018-07-03
Expected to finish
2023-01-03
Last updated by the study team
2024-10-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.